Tagline
Three tagline candidates for mAbV. Each supports the shield-V mark and the core narrative: monoclonal antibodies as immediate, engineered protection. The tagline sits beneath the wordmark in the brand hierarchy.
mAbV
"Protection by design"
Echoes the shield without explaining it. "By design" nods to the engineered, AI-discovered nature of the antibodies without saying so explicitly. Works for both audiences: investors read intentionality and strategic positioning; scientists read designed molecules and rational drug design.
Says nothing clinical. Makes no efficacy claims. Four syllables of breathing room under the wordmark. Fits stealth mode perfectly.
mAbV
"Designed to protect"
Same ingredients as Option 1, reversed. More active and direct — the verb "designed" leads, placing agency on mAbV as the creator. "To protect" states the purpose plainly.
Slightly more assertive. Could be read as closer to a claim than Option 1, though technically it describes intent, not outcome. Best suited if mAbV wants to project confidence and forward motion rather than quiet authority.
mAbV
"Precision protection"
Alliterative, clean, memorable. Two words that compress the whole mAbV story: precise engineering + protective outcome. The rhythm sticks.
The risk: "precision" is heavily used in biotech already (precision medicine, precision oncology) and might anchor mAbV to a therapeutic category it doesn't belong to. Strongest if mAbV wants to lean into the technical/scientific register. Weakest if differentiation from existing biotech language matters.
Usage guidance
The tagline sits in the brand hierarchy beneath the wordmark and above any descriptive copy. It appears:
- On the gateway landing page, between the mAbV wordmark and the "Design System" label
- On presentation title slides, beneath the logo lockup
- In email signatures and document headers (optional)
The tagline is always set in uppercase, light weight, with wide letter-spacing to maintain the clean, clinical aesthetic established in the typography system.